25th Annual U.S. Psychiatric and Mental Health Congress

®®

COMPLETESCHEDULE &

PROGRAMSCIENTIFIC Program

ChooSE From morE ThaN 80 ExCITINg SESSIoNS • Interact wIth over 85 exhIbItors

november 8-11, 2012 • San diego Convention CenterregIster before october 5th for only $699! call: 800-237-7285 ext. 233 or vIsIt psychcongress.com

Please visit www.sawcfall.com.2 RegisteR eaRly and save at www.sawcfall.com.

Table Of COnTenTs4 steering Commitee and faculty6 scientific Program20 education annex21 exhibitors22 Hotel and Travel23 Registration

RegisteR eaRly and saveRegisteR today: www.psychcongRess.com2

lOgisTiC and meeTing PROvideR

HmP Communications, llC83 General Warren Blvd., Suite 100Malvern, PA 19355Toll-free: 800-237-7285Phone: 610-560-0500Fax: 610-560-0502www.hmpcommunications.com

sPOnsOR and eduCaTiOn PROvideR

Cme llC/naCCme300 Rike Drive, Suite AMillstone Township, NJ 08535Phone: 609-371-1137Fax: 609-371-2733www.cmellc.com

deaR menTal HealTH PRaCTiTiOneR:I’ve been involved in both clinical and academic psychiatry for many years, and this experience has really brought home to me how unique and valuable the U.S. Psychiatric and Mental Health Congress truly is. As I think about academic meetings, a lot of data are presented and often the information is only tangentially relevant to the practicing clinician.

What makes Psych Congress so unique is that it manages to bring cutting-edge science together in ways that have immediate clinical implications. Psych Congress speakers do a fantastic job of not just reporting facts and figures, but of synthesiz-ing these data to tell a larger story. Sometimes the story is practical and immediately relevant; other times, the story is more abstract and inspiring for future directions of mental health care.

For the practicing mental health practitioner, there is nothing like Psych Congress. I know of no other event that provides so broad a range of teaching on topics central to our work and improving patient outcomes.

As the program chair of this 25th annual meeting, I invite you to join us to see for yourself how impactful this event is. I look forward to seeing you in San Diego!

Respectfully,

Charles Raison, MD

2012 Psych Congress Program Chair

®®

LLC,TM

Celebrating 25 Years of Optimal education for mental Health Professionals

RegisteR today: call 800-237-7285, ext. 233 RegisteR eaRly and save 3

Who should attend?Psych Congress is designed for psychiatrists, primary care physicians, psychiatric nurses, phy-

sician assistants, psychologists, and other health care professionals who seek to improve their

care for patients with mental health disorders and the outcomes resulting from that care.

Instructional level: Intermediate

learning Objectives After completing this educational program, participants should be able to do the following:

1. Identify the etiology, pathophysiology, and neural pathways of various psychiatric disorders and their effects on patients.

2. Increase ability to assess psychiatric disorders as well as patients’ overall health, including comorbidities, with the

goal of improving diagnosis and treatment.

3. Implement evidence-based models on the use of psychotherapeutic and pharmacotherapeutic interventions to

develop treatment plans, predict treatment response, optimize remission, and prevent relapse.

4. Employ strategies to identify and remove barriers to treatment in order to improve patient outcomes in the acute

and long-term management of psychiatric disorders.

geneRal sCHeduleThursday, november 8

7:30 a.m.–8:00 a.m. Welcome 8:00 a.m.–8:30 a.m. Breakfast 8:30 a.m.–11:45 a.m. Educational Sessions 11:45 a.m.–12:30 p.m. Lunch Break 12:00 p.m.–1:30 p.m. Lunch Professional Medical Education Presentation 12:30 p.m.–7:15 p.m. Educational Sessions 7:30 p.m.–8:30 p.m. Restoring Balance Workshops

friday, november 9 8:00 a.m.–8:30 a.m. Breakfast 8:30 a.m.–9:30 a.m. Breakfast Professional Medical Education Presentation 8:30 a.m.–11:45 a.m. Educational Sessions 11:00 a.m.– 4:00 p.m. Exhibit Hall and Education Annex 12:00 p.m.–12:30 p.m. Lunch Break12:00 p.m.–1:30 p.m. Lunch Professional Medical Education Presentation 12:30 p.m.–2:00 p.m. Educational Sessions 2:00 p.m.–4:00 p.m. Exhibit Hall and Education Annex 4:00 p.m.–7:15 p.m. Educational Sessions 7:30 p.m.–8:30 p.m. Restoring Balance Workshops

saturday, november 10 8:00 a.m.–8:30 a.m. Breakfast 8:30 a.m.–9:30 a.m. Breakfast Professional Medical Education Presentation 8:30 a.m.–11:45 a.m. Educational Sessions 11:00 a.m.–4:00 p.m. Exhibit Hall and Education Annex 12:00 p.m.–12:30 p.m. Lunch Break12:00 p.m.–1:30 p.m. Lunch Professional Medical Education Presentation 12:30 p.m.–2:00 p.m. Educational Sessions 2:00 p.m.–4:00 p.m. Exhibit Hall and Education Annex 4:00 p.m.–7:15 p.m. Educational Sessions 7:30 p.m.–8:30 p.m. Restoring Balance Workshops

sunday, november 11 8:00 a.m.–8:30 a.m. Breakfast 8:30 a.m.–11:45 a.m. Educational Sessions 12:00 p.m.–12:30 p.m. Lunch Break 12:30 p.m.–3:45 p.m. Educational Sessions

Earn Up To

30 CME/CE Credits

4

®® 2012 Psych congress faCulTY

RegisteR eaRly and saveRegisteR today: www.psychcongRess.com

2012 Psych congress sTeeRing COmmiTTeeCME LLC is partnering with six respected minds in the fields of psychiatry and psychology to make 2012 Psych Congress a practical and relevant educational experience.

Charles Raison, md2012 PsyCh Congress PROgRam CHaiRAssociate Professor, Department of Psychiatry, University of Arizona College of Medicine; Barry and Janet Lang Associate Professor, John & Doris Norton School of Family and Consumer Sciences, University of Arizona, Tucson, AZ; Mental Health Expert/Mind-Body Consultant, CNNHealth.com; Scientific President, European Association of Clinical Psychoneuroimmunology

Rakesh Jain, md, mPHDirector of Psychiatric Drug Research R/D Clinical Research Center, Lake Jackson, TX; Associate Clinical Professor, Department of Psychiatry and Behavioral Sciences, Uni-versity of Texas Medical School at Houston, Houston, TX

saundra Jain, Psyd, mba, lPCExecutive Director, Mental Aerobics Project, Lake Jackson, TX

andrew Penn, Rn, ms, nP, Cns, aPRn-bC Psychiatric Nurse Practitioner Kaiser Perman-ente. Redwood City, CA; Assistant Clinical Pro-fessor, University of California, San Francisco, San Francisco, CA

Jon W. draud, ms, mdCme llC PsYCHiaTRY CliniCal diReCTORClinical Professor of Psychiatry, University of Tennessee College of Medicine, Memphis, TN; Medical Director of Psychiatry, Addiction Medicine Services; Baptist Hospital, Nash-ville, TN; Middle Tennessee Medical Center, Murfreesboro, TN; Private Practice, Adult and Adolescent Psychiatry

marc e. agronin, md Medical Director for Mental Health and Clinical Research, Miami Jewish Health Systems, Miami, FL; Affiliate Associate Professor of Psychiatry and Neurology, University of Miami Miller School of Medicine, Miami, FL

lori R. daniels, Phd Vet Center/Readjustment Counseling Services, Department of Veterans Affairs, Portland, OR

Karl doghramji, md Professor of Psychiatry, Neurology, and Medicine, Medical Director, Jefferson Sleep Disorders Center, Thomas Jefferson University, Philadelphia, PA

Craig l. donnelly, md Professor of Psychiatry and Pediatrics, Dartmouth Medical School, Hanover, NH; Chief, Section of Child and Adolescent Psychiatry, Dartmouth-Hitchcock Medical Center, Department of Psychiatry, Lebanon, NH

m. Carmela epright, Phd Associate Professor, Philosophy, Furman University, Greenville, SC; Ethics Consultant, The Medical University of South Carolina, Charleston, SC; Ethics Consultant, Greenville Hospital System, Greenville, SC

gregory franchini, md Director, Wellness Program, University of New Mexico School of Medicine, Albuquerque, NM

noel C gardner, md, mdiv Adjunct Professor, University of Utah, Salt Lake City, UT

almari ginory, dO Forensic Fellow, University of Florida, Gainesville, FL; Assistant Professor, University of Florida, Gainesville, FL

ian H. gotlib, Phd David Starr Jordan Professor of Psychology, Stanford University, Stanford, CA

Kevin gray, md Associate Professor, Departments of Psychiatry and Neurology, University of Texas Southwestern Medical Center, Dallas, TX

vladimir maletic, md, msClinical Professor of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, Columbia, SC; Consulting Associate, Division of Child and Adolescent Psychiatry, Department of Psychiatry, Duke University, Durham, NC

advisORY bOaRd


®®2012 Psych congress faCulTY

doris greenberg, md Developmental and Behavioral Pediatrician and Associate Clinical Professor of Pediatrics, Mercer University School of Medicine, Savannah, GA; Director of Behavioral and Developmental Pediatric Rotation, Residency in Pediatrics, Memorial University Medical Center, Savannah, GA; Board Certified in Pediatrics and Developmental and Behavioral Pediatrics

Judith grisel, Phd Professor and Chair, Department of Neuroscience, Furman University, Greenville, South Carolina

Robert l. Hendren, dO Professor and Vice Chair, University of California, San Francisco, San Francisco, CA

israel C. Kalman, ms Director, Bullies to Buddies, Inc., Staten Island, NY; Speaker, Cross Country Education, Nashville, TN

Walter H. Kaye, md Professor of Psychiatry, University of California, San Diego, San Diego, CA; Program Director, Eating Disorders Program, University of California, San Diego, San Diego, CA

steven a. King, md, ms Clinical Professor of Psychiatry, New York University School of Medicine, New York, NY

Kurt Kroenke, md Professor of Medicine; Indiana University School of Medicine; Indianapolis, IN

stephen b. levine, md Co-Director, Center for Marital and Sexual Health, Beachwood, OH; Clinical Professor of Psychiatry, Case Western Reserve School of Medicine, Cleveland, OH

lorin lindner, Phd Clinical Psychologist, Private Practice, Frazier Park, Valencia, Bakersfield, Beverly Hills, CA

William lopez, md Lead Medical Director, Acute Behavioral Regional Team, Cigna Healthcare, Eden Prairie, MN

stuart l. lustig, md, mPH Medical Director, Cigna Healthcare, Glendale, CA; Adjunct Associate Professor, Department Psychiatry, University of California San Francisco, San Francisco, CA

Oren mason, md Founder and Director, Attention MD, Grand Rapids, MI; Assistant Professor, Michigan State College of Human Medicine, Grand Rapids, MI

laura m. mayol sabatier, md Child and Adolescent Fellow, University of Florida, Gainesville, FL

bill mcCarberg, md Founder, Chronic Pain Management Program, Kaiser Permanente, San Diego, CA; Adjunct Assisting Clinical Professor, University of California, San Diego, CA

laura J. miller, md Vice Chair for Academic Clinical Services, Department of Psychiatry, Brigham and Women’s Hospital, Boston, MA; Professor, Harvard Medical School, Boston, MA; Director, Women’s Mental Health Division, Department of Psychiatry, Brigham and Women’s Hospital, Boston, MA

michael C. mithoefer, md Private Practice of Psychiatry and Clinical Research, MAPS, Mount Pleasant, SC; Clinical Assistant Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC

david n. neubauer, md Associate Professor, Johns Hopkins University School of Medicine, Baltimore, MD douglas l. noordsy, md Associate Professor of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, NH; Associate Editor, Journal of Dual Diagnosis

george i. Papakostas, md Director, Treatment-Resistant Depression Studies, Massachusetts General Hospital, Boston, MA; Associate Professor of Psychiatry, Harvard Medical School, Boston, MA

anton P. Porsteinsson, md William B. and Sheila Konar Professor, University of Rochester School of Medicine and Dentistry, Rochester, NY

sheldon H. Preskorn, md Professor of Psychiatry, University of Kansas School of Medicine, Wichita, KS; Chief Science Officer, Kansas University Clinical Trial Unit, Wichita, KS

alya Reeve, md, mPH Principal Investigator, Continuum of Care, University of New Mexico, Albuquerque, NM; Associate Professor, Psychiatry, Neurology, and Pediatrics, University of New Mexico, Albuquerque, NM

Phillip J. Resnick, md Professor of Psychiatry, Case Western Reserve University, Cleveland, OH

gerard sanacora, md, Phd Professor, Yale University, School of Medicine, New Haven, CT

david J. scheiderer, md, mba, dfaPa Director of Education, Integrative Psychiatry, Inc., Sarasota, FL; Preisdent, Tiberius Enterprises, Roanoke, VA

Charles schulz, md Professor and Head, University of Minnesota, Minneapolis, MN

Kenneth J. shapiro, Phd Executive Director, Animals and Society Institute, Ann Arbor, MI

david sheehan, md, mba Distinguished University Health Professor Emeritus; University of South Florida College of Medicine; Tampa, FL

stephen v. sobel, md Clinical Instructor, University of California, San Diego, School of Medicine, San Diego, CA; Consulting Psychiatrist, NFL San Diego Chargers, San Diego, CA; Consulting Psychiatrist, MLB San Diego Padres, San Diego, CA

murray b. stein, md, mPH Professor of Psychiatry and Family and Preventive Medicine, University of California San Diego, La Jolla, CA; Staff Psychiatrist, VA San Diego Healthcare System, La Jolla, CA

michael e. Thase, md Professor of Psychiatry, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA; Staff Psychiatrist, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA; Adjunct Professor of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA

matthew Tierney, nP, msn Director, Office-Based Buprenorphine Induction Clinic, San Francisco General Hospital, Department of Psychiatry, San Francisco, CA; Assistant Clinical Faculty, University of California, San Francisco, School of Nursing, San Francisco, CA

Karen dineen Wagner, md, Phd Marie B. Gale Centennial Professor and Vice Chair, Department of Psychiatry, The University of Texas Medical Branch, Galveston, TX; Director, Division of Child and Adolescent Psychiatry sara Waller, Phd Associate Professor, Philosophy, Montana State University, Bozeman, MT

Tonia l. Werner, md Assistant Professor and Chief of Forensic Psychiatry, University of Florida, Gainesville, FL

Paul Zarkowski, md Clinical Assistant Professor, University of Washington, Seattle, WA

6

®® SCIENTIFIC PROGRAM


®®

2012 sCienTifiC PROgRam OveRvieW *as of August 9, 2012; sessions and schedule subject to change without notice.

The 2012 Psych Congress Scientific Program focuses on sessions that provide knowledge and tools from which mental health care professionals may confidently diagnose disorders and develop effective individualized treatment plans to achieve patient wellness by applying evidence-based man-agement into daily practice. The program covers a broad spectrum of topics and educational formats, providing more than 80 sessions to choose from.

THuRsdaY, nOvembeR 8, 2012

8:30 a.m.–10:00 a.m.

facilitating systems Change in schizophrenia manage-ment: a dual Curriculum for mental Health Care Profes-sionals and managed Care to align Treatment strategies with Hedis measuresThe goal of this activity is to address barriers to the effective management of schizophrenia, as well as to discuss managed care strategies to better enable mental health care professionals to improve patient outcomes and quality of life.Track(s): TBAspeaker(s): TBAThis activity is supported by an educational grant from Janssen, Di-vision of Ortho-McNeil-Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC.

Cancer and behavioral disturbances: mind-body PerspectivesThis session brings understandings from mind-body science to bear on the complex relationships that pertain between cancer and a variety of behavioral disturbances, including depression, anxiety, and fatigue. Adopting a perspective that sees psychological, social, and immune processes as inextricably linked provides novel insights into the pathophysiology and treatment of depression, anxiety, and fatigue that occur in the context of cancer and/or its treatment. This session explores the pragmatic treatment implica-tions of these insights.Tracks: Cancer Psychiatry, Mood Disorders speaker: Charles Raison, MD

attacking anxiety disordersAnxiety disorders are among the most prevalent mental disorders seen in the community, primary care, and psychiatry specialty prac-tice. Anxiety disorders are often comorbid with major depression, substance use disorders and, frequently, other medical disorders. This session provides an update on the pharmacotherapeutic management of several of the most common anxiety disorders. If relevant, differential pharmacotherapy of these disorders will be discussed, including expectations for responses when treat-ing patients with certain comorbid conditions. The session also discusses cognitive-behavioral therapeutic and measurement-based care approaches that can be implemented within the context of a predominantly psychopharmacotherapeutically oriented practice to improve patient outcomes.Track: Anxiety Disordersspeaker: Murray Stein, MD, MPH

social security disability for PsychiatryAs patients apply for Social Security disability in ever-higher num-bers, treating mental health care professionals must have an un-derstanding as to what is expected of them as treatment sources. This session covers the specific disability policies and guidelines utilized by the Social Security Administration. It also covers criteria to be used by physicians serving as consulting evaluators for state Social Security offices as well as for those serving, or interested in serving, as medical experts at the federal level.Tracks: Practice Management, Forensic Psychiatryspeaker: Stuart Gitlow, MD, MPH, MBA

sCienTifiC PROgRam THuRsdaY, nOvembeR 8, 2012


®®

10:15 a.m.–11:45 a.m.

adHd across the lifespan: diagnostic and Treatment ConsiderationsAttention-deficit/hyperactivity disorder (ADHD) is a disorder in which symptoms evolve over time, necessitating a wider develop-mental perspective when diagnosing, recognizing comorbid condi-tions, and treating ADHD across age groups. This session presents the implications of ADHD across the lifespan and differences in clinical presentation, functional impairments, and diagnostic strate-gies. The session reviews practical approaches to diagnosis, includ-ing using developmentally appropriate rating scales and treatment strategies in light of commonly occurring comorbidities.Track: ADHDspeaker: Craig Donnelly, MD

a fun, Powerful Technique for Teaching Children How to stop being bulliedThe problem of bullying has become of increasing concern as more and more children take their lives because they cannot tolerate being bullied. Unfortunately, mental health care professionals are often at a loss for how to help victims of bullying, because the orthodox approach to the problem requires them to serve as police officers, protecting children from each other instead of equipping them to solve their problem. This workshop provides a simple and fun approach to quickly teach victims of bullying the knowledge and skills to stop being bullied.Tracks: Child and Adolescent Psychiatry, Psychotherapyspeakers: Doris Greenberg, MD; Israel Kalman, MS, MD

mdma-assisted Psychotherapy for Posttraumatic stress disorder: Recent and Current Research into a Promising new TreatmentResearch into MDMA-assisted psychotherapy is a relatively recent area of investigation that is growing quite rapidly, and about which there has been considerable media attention but few papers in the medical literature. The first completed controlled trial of MDMA-as-sisted psychotherapy was published in the Journal of Psychophar-macology in 2010. This session presents the history of MDMA as a possible therapeutic agent and current research around the world on MDMA-assisted psychotherapy for posttraumatic stress disorder.Track: Posttraumatic Stress Disorderspeaker: Michael Mithoefer, MD

addictive disease: a Practical guideEven those who think of addiction as a chronic life-threatening dis-ease often categorize it separately from other similar illnesses, such as hypertension and diabetes. This session focuses on a method of considering the three building blocks of addictive disease: genetic, environmental, and sociologic. This will help attendees regard ad-diction as one would consider other, similar medical conditions.Track: Substance Abuse, Addiction and Deterrencespeaker: Stuart Gitlow, MD, MPH, MBA

Treating the Whole Patient: examining Receptors in de-pression: enhancing Opportunities and minimizing RiskThis session on depression will examine the latest information on the role of receptors in the regulation of mood and the genesis of depression, and translate this deep knowledge into an understanding of the roles different receptor agonists and antagonists play in the treating depression to improve patient care and treatment outcomes.Tracks: Mood Disorders, Wellnessspeakers: Jon W. Draud, MS, MD; Rakesh Jain, MD, MPH

12:00 p.m.–1:30 p.m.

Professional medical education PresentationTopic: schizophreniaLunch will be served.This presentation is provided by Sunovion Pharmacueticals, Inc.

sCienTifiC PROgRam THuRsdaY, nOvembeR 8, 2012

TWP

8

®® sCienTifiC PROgRam THuRsdaY, nOvembeR 8, 2012


12:00 p.m.–2:00 p.m.

new and emerging multi-target approaches for the Treat-ment of major depressive disorderThe goal of this initiative is to provide mental health care profes-sionals with knowledge on new and emerging multi-target agents for the treatment of major depressive disorder (MDD), as well as strategies for individualizing treatment and improving adherence among patients with MDD.Track: Mood Disordersspeakers: Gustavo Alva, MD, DFAPA; Vladimir Maletic, MD, MSThis session is supported by an educational grant from Takeda Pharmaceuticals Inc.

Time for a Psychiatric gut Check: The HPa-gut axis and mood symtpomsThe goal of this session is to provide health care professionals with the tools required to identify patients with depression and other psychiatric illnesses, who possess features that suggest cytokine sensitivity (inflam-mation) emanating from the the gastrointestinal system. Such tools will help health care professionals enhance and expand their repertoires of treatment and management options, thereby yielding improved patient care, clinical outcomes, and general wellness.Track: Mood Disordersspeaker: David Scheiderer, MD, MBA, DFAPA

update on Treatment of bipolar disorder in Children and adolescentsThis session provides mental health care professionals with new information about treatments for bipolar disorder (BD) in children and adolescents. The relative benefits and risks of atypical antipsychotics, mood stabilizers, and alternative therapies will be discussed to improve mental health care professionals’ treatment strategies for BD in children and adolescents.Tracks: Mood Disorders, Child and Adolescent Psychiatryspeaker: Karen Dineen Wagner, MD, PhD

2:15 p.m.–3:45 p.m.

spice, bath salts, and salvia: understanding emerging drugs of abuseSubstances of abuse often evolve faster than clinical or legal systems. This session examines three emerging drugs that can be abused: synthetic cannabinoids (spice), synthetic cathinone stimulants (bath salts), and the naturally occurring hallucinogen Salvia divinorum. Discussions include the epidemiology, risks, and potential therapeutic uses of these drugs.Track: Substance Abuse, Addiction and Deterrencespeaker: Andrew Penn, RN, MS, NP, CNS

Physician Well-being: Who Cares?Mental health care professionals are experiencing an ever-increasing barrage of responsibilities and expectations. This session explores mental health care professionals’ apparent lack of concern for their own well-being as they strive to maintain that of their pa-tients. It also identifies stresses and situations that provoke stress, while offering potential approaches to their management.Track: Wellnessspeaker: Gregory Franchini, MD

understanding and managing Traumatic stressThis session provides an overview of the epidemiology of posttrau-matic stress disorder (PTSD), emphasizing recent studies in the mili-tary. It links these data pointing to a profound need for treatment with an evidence-based update on treating acute stress disorder and PTSD, and highlights pharmacotherapeutic approaches.Track: Posttraumatic Stress Disorderspeaker: Murray Stein, MD, MPH

Optimizing the managed Care doc to doc: new strategies That Work, from the Perspective of man-aged Care’s Peer ReviewersThe goal of this panel-led presentation is to present inpatient clinicians who do managed care peer reviews on behalf of their patients with a deeper understanding of how to better advocate for their patients within the framework of typical level-of-care guidelines. Presenters, both of whom are medical directors con-ducting peer reviews for a health care company, will discuss tactics that will make clinicians in inpatient settings more savvy case presenters who can move beyond the admission or continued-stay criteria about dangerousness to self or others in order to optimize clinical care.Tracks: Assessment and Adherence, Practice Management speakers: Stuart L. Lustig, MD, MPH; William Lopez, MD


®®sCienTifiC PROgRam THuRsdaY, nOvembeR 8, 2012

Treating the Whole Patient expert Course: expert examination of Critical issues in Receptor-based Pharmacology in depressionThese engaging, small-group discussions aim to integrate scientific advances and theoretical knowledge into best clinical practice to achieve the optimal balance between treatment efficacy and potential risks, while promoting therapeutic collaboration, treatment adherence, and wellness practices. The intimate learning environment encourages engagement on possible diagnostic, treatment and management strategies using case examples. Enrollment is limited and pre-registration is required for all Expert Courses.Tracks: Mood Disorders, Wellness speakers: Jon W. Draud, MS, MD; Rakesh Jain, MD, MPH*Pre-registration is required for this session.

4:00 p.m.–5:30 p.m.

Preventing Cognitive decline in Your PatientsAlzheimer’s disease and other dementias have become major health concerns in aging societies, making early identification of at-risk subjects of utmost importance. To be discussed: biomarker and diagnostic technologies and possible interventions for preventing cognitive decline in middle-aged and elderly patients.Track: Dementia and Cognitive DisordersAnton Porsteinsson, MD

implementing effective insomnia management: important issues in evaluation and TreatmentInsomnia is prevalence in the general population and quite com-mon among people with mental health disorders. This session reviews diagnosing insomnia; highlights common challenges in evaluating patients with sleep disturbances; considers key advan-tages and disadvantages of the major treatment options, including cognitive-behavioral and pharmacotherapeutic approaches; and

emphasizes consensus clinical guidelines. Promoting good sleep habits and treating sleep disorders will be emphasized as impor-tant components to wellness.Track: Sleep Disordersspeaker: David Neubauer, MD

bipolar disorder in WomenThis session summarizes clinically relevant research about gender differences in bipolar disorder (BD) and the influences of reproductive-cycle events on BD in women. Discussions include a review of pharmacologic considerations unique to women, such as dosing strategies across the menstrual cycle and prescribing mood-stabilizing agents during pregnancy and lactation, and applications of interpersonal and social rhythm therapy, family-focused therapy, and cognitive-behavioral therapy to women with BD at different reproductive stages.Track: Women’s Mental Healthspeaker: Laura Miller, MD

evidence update for a novel model for understanding and Treating autismRecent research about the etiology of autism spectrum disorders (ASD) suggests novel models and mechanisms may affect ASD as-sessment and treatment. What we know has grown exponentially over the past two years. This session aims to provide an update and increase consideration of these novel mechanisms in their research and integrative practices. It also introduces a new paradigm for understanding the neurodevelopmental, gene X-environment inter-action in the etiology and uses this to define treatment targets.Tracks: Autism Spectrum/Developmental Disorders, Neurology/Neurosciencespeaker: Robert Hendren, DO

brief, brief, brief! scientific breakthroughs and Clinical ap-plications of ultra short meditation TrainingMeditation practices are centuries old and the benefits documented, but use in clinical settings is quite low. Meditation practices are often associated with long, uncomfortable periods of sitting, searching for nirvana. This session offers another option: brief meditation, as little as one hour of training and practice. Discussions include scientific and practical information on its benefits.Track: Psychotherapyspeaker: Saundra Jain, MA, PsyD, LPC

5:45 p.m.–7:15 p.m.

To Test or not to Test: The use of biological markers and laboratory-based Testing in Clinical Psychiatric PracticeThe goal of this session is to provide health care professionals the tactics needed to identify and employ currently available tests de-signed to expand our treatment options with the aim of improving patient care, clinical outcomes, and general health.Track: Assessment and Adherence speaker: David Scheiderer, MD, MBA, DFAPA

management of Treatment-Resistant depression in Children and adolescentsThis session provides mental health care professionals with clini-cally relevant information about strategies to manage treatment-resistant depression in children and adolescents. Augmentation with other medications, psychotherapy, and alternative treatment modalities are among the methods to improve responses in youth who fail to respond to initial treatment with an antidepressant.Tracks: Mood Disorders, Child and Adolescent Psychiatry speaker: Karen Dineen Wagner, MD, PhD

TWP

10

®® sCienTifiC PROgRam fRidaY, nOvembeR 9, 2012


ethics and evidence-based PsychiatryMental health care professionals are often unfamiliar with standard principles of ethics and how they apply to their field. This session ex-plores the ethical implications of practicing evidence-based Psychiatry. This session explains what evidence-based medicine means in mental health care, and the ways in which this paradigm is and is not ap-propriate for diagnosing and treating psychiatric patients.Track: Ethics speaker: M. Carmela Epright, PhD

management of Transgendered Patients Through the lifecycleThe media glamorize the treatment of gender identity disorder, which tends to distort the ordinary clinical realities and comorbidities of these patients. This session provides a balanced perspective on interventions for transgender problems as they present in childhood, adolescent, and early, middle and late adulthood. Discussions include defining the erotic and sexual components of sexual identity and acquainting participants with the clinical and political controversies embedded in somatic, psychotherapeutic, and advocacy interventions.Track: Sexual Disordersspeaker: Stephen Levine, MD

fRidaY, nOvembeR 9, 2012

8:00 a.m.–9:30 a.m.

Professional medical education PresentationTopic: major depressive disorderBreakfast will be served.This presentation is provided by Mylan, Inc.

8:00 a.m.–10:00 a.m.

evidence-based Pharmacologic strategies for Partial or non-response to Treatment in major depressive disorderThe goal of this activity is to present guideline-concordant approaches to the pharmacologic management of partially responsive and treatment-resistant depression, with the ultimate goal of achieving sustained remission in patients with major depressive disorder.Track: Mood Disordersspeakers: Bradley Gaynes, MD, MPH; Joseph Goldberg, MD; Sanjay Johan Mathew, MDThis session is supported by an educational grant from Otsuka America Pharmaceutical.

8:30 a.m.–10:00 a.m.

new approach to adHd medication —Combination TherapyCombination therapy has been used informally in mental health care, but new evidence is emerging that combination therapy is safe and effective for difficult and treatment-resistant cases of attention-deficit/hyperactivity disorder (ADHD). This session presents research review and multiple case histories that will demonstrate a variety of approaches to combination therapy in ADHD. Discussions include practical methods to optimize efficacy and improve tolerability.Track: ADHDspeaker: Oren Mason, MD

anger Control made easyPeople get angry because they feel abused by others. The truth is usually the other way around: people continue to get abused because they are getting angry. This workshop demonstrates a quick and powerful method for teaching patients to solve relationship problems and stop being abused by controlling their anger.Tracks: Abuse/Trauma, Psychotherapy speakers: Doris Greenberg, MD; Israel Kalman, MS, MD

using the neurodevelopmental formulation in Clinical PracticeAlthough our understanding of mental disorders is shifting through neuroscience research, a clinically useful neurodevelopmental model has not been established for assessment and treatment planning. The goal of this session will be to discuss a neurodevelopmental model developed based on new research as it relates to mental disorders that emerge in childhood and adolescence, with a particular focus on schizophrenia, affective disorders, autism and attention-deficit/hyperactivity disorder. This session aims to provide a practical, state-of-the-art, understanding of etiology and treatment planning. Gene sequencing, imaging, epigenetics, relating animal models to humans, commonalities and biomarkers guiding treatment, and targeted treat-ments across disorders will be emphasized.Tracks: Neurology/Neuroscience, Child and Adolescent Psychiatryspeaker: Robert Hendren, DO

The modern Treatment of erectile dysfunction: Organic and PsychogenicPsychiatric patients have at least as much erectile dysfunction (ED) as the general population (increases with age), but their physi-cians generally do not focus on the topic. This session provides the evidence-based data and the attitudes required to improve the assessment and effective treatment of ED.Tracks: Sexual Disorders, Psychotherapyspeaker: Stephen Levine, MD


®®sCienTifiC PROgRam fRidaY, nOvembeR 9, 2012

10:15 a.m.–11:45 a.m.

assessment and mangement of major depressive disorderEmerging evidence suggests that several clinical factors may be relevant with regard to predicting the likelihood of responding to standard antidepressant therapy (predictors), as well as in defining sub-populations of patients whose depression may preferentially respond to one given treatment over another (moderators of treatment outcome). Ultimately, being able to select an appropriate treatment based on clinical presentation or the presence of biologic markers may help improve the standard of care for major depressive disorder. The goal of this session is to review a standard approach for evaluating a patient with a major depressive episode, followed by a conceptual ap-proach to first-line treatment selection with an emphasis on identifying common pitfalls of contemporary antidepressant therapy.Track: Mood Disordersspeaker: George Papakostas, MD

Traumatic stress Psychotherapy using an integrated approachAlthough recent trends in posttraumatic stress disorder treatment focus on a handful of manualized interventions, an integrated psychotherapy approach to counseling trauma survivors may be a more appropriate approach, given the varying and unique emo-tional needs of each trauma survivor. Conceptualizing traumatic event response as also including multiple levels of loss may provide mental health providers with a model in which to strategically address these various needs. The goal of this session is to discuss the benefits of using multiple theories and interventions in order to avail client-centered, emotion-focused psychotherapy — from which cognitive and emotional processing of traumatic memories can occur, toward the outcome of relieving long-standing stuck cognitions and emotions.Tracks: Posttraumatic Stress Disorder, Psychotherapyspeaker: Lori Daniels, PhD

The X factor (alprazolam): friend or foe?Alprazolam is in the news everywhere. The recent deaths of mul-tiple celebrities involving alprazolam misuse are stark testimony to this deadly problem, yet countless clinicians and patients report benefit from this medication. What are we clinicians to make of this? Is alprazolam a friend or foe? This session offers both sides of this challenging story so that we clinicians can individually make up our minds about the potential benefits and the pitfalls of using this controversial medication.Track: Anxiety Disorders speakers: Rakesh Jain, MD, MPH; Saundra Jain, MA, PsyD, LPC

broadening Horizons: a focus on Current and emerging Therapies in schizophreniaThe goal of this activity is to give mental health care professionals a better understanding of the benefits and limitations of currently available antipsychotic agents and knowledge of emerging schizo-phrenia treatments.Track: Schizophreniaspeakers: Christoph U. Correll, MD; Diana Perkins, MD, MPHThis session is supported by an educational grant from Lilly USA, LLC.

exhibit Hall and education annex11:00 a.m.– 4:00 p.m

12:00 p.m.–1:30 p.m.

Professional medical education PresentationTopic: depressive disordersLunch will be served.This presentation is provided by Takeda Pharmacueticals, Inc.

Professional medical education PresentationTopic: schizophreniaLunch will be served.This presentation is provided by Sunovion Pharmaceuticals, Inc.

12:30 p.m.–2:00 p.m.

schizophrenia: The Role of symptom domains on Patient OutcomesThe goal of this initiative is to improve the competence and confidence of mental health professionals in identifying the primary and secondary symptom domains of schizophrenia while address-ing them more effectively with existing and novel treatments to optimize outcomes for patients.Track: Schizophrenia speakers: Henry Nasrallah, MD; Joseph McEvoy, MDThis session is supported by an educational grant from Genentech, Inc.

introduction to neuroethics for CliniciansThis session explores multidisciplinary implications of the rap-idly advancing field of neuroscience. Participants will consider a range of ethical, moral, and medical issues associated with neuroscience research including how these studies inform an understanding of autonomous selves, notions of free will, and conceptions of legal and moral responsibility. Discussions include applications to psychiatric treatment, personal enhance-ment, and social, economic and political objectives.Track: Ethics speaker: M. Carmela Epright, PhD; Judith Grisel, PhD; Sara Waller, PhD

12

®® sCienTifiC PROgRam fRidaY, nOvembeR 9, 2012


Cannabis and mental Health: Risks and ResearchMarijuana is a commonly used drug in the United States and pres-ents risks for serious mental health problems. This session describes the effects of marijuana and the dangers posed to mental health, as well as the body’s endogenous cannabinoid system and how it is being researched to develop medications that may treat mental health problems.Tracks: Substance Abuse, Addiction and Deterrence, Neuromodulation speaker: Matthew Tierney, NP, MSN

faith, fundamentalism, and frontal lobe functionRecent high-profile forensic cases involving defendants who espouse conspiracy-based religious or political beliefs, or whose thinking is dominated by extreme fundamentalist religious ideas, have created complex and confusing challenges for U.S. courts and the psychiatric experts who attempt to assist them. This session clarifies the purpose of laws that provide accommodation for individuals with severe mental diseases or defects and the nature of the validity problems with the current DSM/empiric system of diagnosis. It provides a neuroscience-based model for accurately identifying the Axis I, Axis II, and cultural components of mental and behavioral function (or dysfunction) in these defendants as well as other complex clinical cases. Finally, this session provides an empiric, three-domain model for conceptualizing religion, as well as a developmental model for distinguishing healthy and unhealthy forms of religious experience, and guidelines for optimal therapeu-tic engagement with the religiously committed patient.Tracks: Forensic Psychiatry, Neurology/Neuroscience Wellnessspeaker: Noel Gardner, MD, MDiv

meeT THe eXPeRTs2:00 p.m–2:30 p.m, 2:45 p.m–3:15 p.m, and 3:30 p.m–4:00 p.m

unopposed exhibit Hall and education annex

2:00 p.m.– 4:00 p.m

4:00 p.m.–5:30 p.m.

Personalized approaches to Treating depression: folate-based TherapiesThe goal of this activity is to provide mental health care profes-sionals with an increased awareness and understanding of augmentation/combination strategies with folate-based thera-pies when developing individual treatment plans to improve outcomes of patients with MDD.Track(s): TBAspeaker(s): TBAThis activity is supported by an educational grant from Pamlab, LLC.

Preconception Planning for Women with Psychiatric disordersThis workshop addresses the clinical complexities of planning a pregnancy in the context of a pre-existing psychiatric disorder or risk factors for perinatal psychiatric complications. Using a case-based interactive format, the workshop explores strategies for reducing perinatal and long-term risks to women and their offspring of both untreated mental illness and of pharmacologic treatments. Discussions include ways to modify psychopharmaco-logic regimens and optimize non-pharmacologic interventions.Track: Women’s Mental Health speaker: Laura Miller, MD

divorce: The effects on Children and How to Help lessen the TraumaMillions of children suffer the after-effects of divorce. Courts often impose unworkable visitation and other hardships on the parents and children. This session discusses the effects of divorce on chil-dren and adolescents, how to advise families and courts, and how to assist the children when their families are fractured.Tracks: Child and Adolescent Psychiatry, Forensic Psychiatry speaker: Doris Greenberg, MD

Targeting glutamate in the Quest to develop novel Treatments for mood disordersThe monoaminergic hypothesis of mood disorder pathophysiology has dominated the field for five decades. This session presents the basic neurobiological and pharmacological foundations of the novel class of glutamatergic drugs that are under investigation for the treatment of mood disorders.Tracks: Mood Disorders, Neurology/Neuroscience speaker: Gerard Sanacora, MD, PhD

multiple medication use: Why, How and so What?This presentation will review the extent of multiple medication use, why and how it occurs, what the potential clinical outcomes are, and what clinicians can do manage this issue to optimize patient outcomes.Track: Psychopharmacologyspeaker: Sheldon Preskorn, MD


®®sCienTifiC PROgRam fRidaY, nOvembeR 9, 2012

5:45 p.m.–7:15 p.m.

adHd medication Close-up: angels and devils in the detailsMedication management for patients with attention-deficit/hyperactivity disorder (ADHD) requires careful attention to issues of efficacy and tolerability. Small differences between similar medications can often make large differences in clinical response. A multimedia tour of the first-line medications for ADHD will famil-iarize participants in the details that lead to successful treatment of ADHD.Tracks: ADHD, Assessment and Adherencespeaker: Oren Mason, MD

is Happiness Teachable? Positive Psychology in everyday Clinical PracticeIs happiness something a person can learn? Is it a choice, or are you born with a certain, unchangeable amount? Is this just pop psychology, or does it have a place in our modern treatment ap-proaches? This session reviews data from the school of positive psychology, which stresses that happiness is something we can learn and can teach our patients. The session also offers practical tips on how to incorporate positive psychology into everyday clinical practice.Track: Wellnessspeaker: Saundra Jain, MA, PsyD, LPC

The Keys to Recognizing and effectively Treating bipolar ii disorderBipolar II disorder (BD-II) presents significant challenges to pa-tients, mental health care professionals, and medical treatment professionals. Treatment is complicated with ever changing treat-ment needs and goals, and differs from the treatment of BD-I in important ways. The role of antidepressants in the treatment of BD has become one of the most controversial topics in psychia-

try. This session focuses on clinically relevant, evidenced-based treatment of BD-II.Track: Mood Disordersspeaker: Stephen Sobel, MD

management of Cancer PainPain is frequently experienced by patients with cancer. In addition to the direct suffering pain can cause, if not properly treated, it can result in other problems, such as hopelessness and depres-sion, which mental health care professionals may be asked to address. This session discusses the different types of pain associ-ated with cancer, how cancer pain affects the mental health of patients, and pharmacologic and non-pharmacologic treatment strategies to relieve pain in these patients.Tracks: Cancer Psychiatry, Painspeaker: Steven King, MD, MS

COnTinuing eduCaTiOn CRediTCME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME LLC designates this live activity for a maximum of 30 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider approved by the California Board of Registered Nursing, Provider Number CEP12748 for 30 contact hours.

CME LLC is approved by the American Psychological Association to sponsor continuing edu-cation for psychologists. CME LLC maintains responsibility for this program and its content.

Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion, as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

Other health care professionals should check with their state licensing and certification boards to determine if Psych Congress meets their continuing education requirements.

ReQuiRemenTs fOR CRediT

To be eligible for documentation of credit for each session attended, each participant must participate in the full activity and complete the online general survey and the online evalua-tion form for each session.

disClOsuRe

It is the policy of CME LLC to ensure balance, independence, objectivity and scientific vigor in all sponsored or jointly sponsored educational activities. Any individual in a position to control the content of an educational activity, including course or activity directors, advisory board members, staff, teachers or authors of CME, must disclose all relevant financial relationships and the nature thereof that they or any member of their family have with commercial interest(s). The ACCME describes relevant financial relationships as those in any amount occurring within the past 12 months that create a conflict of interest. Individuals who refuse to disclose will be disqualified from participation in the development, manage-ment, presentation or evaluation of the CME activity.

TeRms and COndiTiOns

All information regarding sessions, symposia, speakers, topics, events, dates, and times is preliminary and subject to change up to and during the 2012 Psych Congress. The total credits that will be available are not guaranteed and subject to change as circumstances require. Attendees are responsible for checking with their state licensing and certification boards to determine if the 2012 Psych Congress meets their continuing education requirements. All updated information will be reflected at www.psychcongress.com as it becomes available. The meeting organizer is not liable for any travel-related penalties, fees, losses, forfeitures, or related damages in the event the meeting is rescheduled or canceled.

COPYRigHT sTaTemenT

Copyright © 2012 by CME LLC, a subsidiary of NACCME, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from CME LLC.

INFORMATION CONTAINED HEREIN IS SUBJECT TO CHANGE WITHOUT NOTICE.

14

®® sCienTifiC PROgRam saTuRdaY, nOvembeR 10, 2012


saTuRdaY, nOvembeR 10, 2012

8:30 a.m.–11:30 a.m.

individualizing Treatment in mdd: The Role of maOis*The goal of this initiative is to provide mental health care profes-sionals with an increased awareness and understanding of the role of monoamine oxidase inhibitors (MAOIs) in major depres-sive disorder (MDD) to be better equipped to provide individual-ized care and improve patient outcomes.Tracks: Mood Disorders, Psychopharmacologyspeakers: George Papakostas, MD (Program Chair); Jon W. Draud, MS, MD; Marlene Freeman, MD; Gerard Sanacora, MD, PhD; Michael Thase, MDThis activty is supported by an educational grant from Mylan Specialty L.P.*Pre-registration is required for this session.

8:30 a.m.–10:00 a.m.

meeting the Challenges of Treating People with Tbi or i/dd: strategies for assessment, management, and Psycho-pharmacologyThe are insufficient practitioners trained in working with people with traumatic brain injury (TBI) and intellectual and/or develop-mental disability (I/DD) who have concurrent mental illnesses. This session introduces the principles for approaching patients who present in atypical fashion, including neurologic difficulties, com-munication challenges, and the latest in psychiatric knowledge.Tracks: Autism Spectrum/Developmental Disorders, Posttraumatic Stress Disorderspeaker: Alya Reeve, MD, MPH

The Child Who isn’t Talking: sorting Out the CausesSince the development of speech and language heralding future academic and social competency, it is important to sort out the reasons for a child who fails to speak on time or a child who speaks in certain restricted environments. This session discusses the most common reasons for language and speech problems: autism, selective mutism, hearing problems, performance anxiety, speech apraxia, articulation disorders, developmental delays, and language problems faced by children who must adjust to a new language. Discussions include selective mutism, a problem that occurs in extremely shy children and can be a barrier between student and teacher.Tracks: Child and Adolescent Psychiatry, Autism Spectrum/De-velopmental Disorders speaker: Doris Greenberg, MD

utility of PHQ-9 and Other brief Psychiatric scales in Clinical PracticeMeasurement-based care for depression and other psychiatric disorders is being advocated and, in some cases, required by payers, quality improvement initiatives, and health care profes-sional organizations. Valid brief self-report scales are a practical means of assessing symptom severity of depression and other common psychiatric disorders and monitoring response to treatment. This session discusses the practical use of scales and screeners, such as the PHQ-9 and several brief measures for anxiety, somatization, and other common psychiatric disorders.Tracks: Mood Disorders, Anxiety Disordersspeaker: Kurt Kroenke, MD

alzheimer’s disease update 2012: The state of the scienceAlzheimer’s disease remains the third most deadly and costly disease in our country, exacting a staggering and growing toll on more than 5 million Americans and an even greater number of caregivers. Several new developments include amyloid-based neuroimaging and the use of immunologic treatments. This ses-sion reviews the latest developments in diagnosis and treatment, including a review of all existing experimental therapies.Tracks: Dementia and Cognitive Disorders, Geriatric Psychiatryspeaker: Marc Agronin, MD

exhibit Hall and education annex11:00 a.m.– 4:00 p.m.

10:15 a.m.–11:45 a.m.

measurement-based Care: Can the use of scales and structured interviews Change the Course of Treatment?Validated rating scales and structured diagnostic interviews are commonly used in research to aid in the diagnosis and assessment of severity of psychiatric disorders and to provide a framework for measuring response and remission. Despite this, their integration into clinical practice is variable even though there are benefits to such measurement-based care. This session demonstrates how rating scales and structured diagnostic interviews can be effectively used to assess and monitor treatment outcomes in depression, as well as measuring residual symptoms and domains of therapeutic interest.Tracks: Assessment and Adherence, Mood Disorders speaker: David Sheehan, MD, MBA


®®sCienTifiC PROgRam saTuRdaY, nOvembeR 10, 2012

breaking free: The Keys to effective Treatment of the Obsessive-Compulsive spectrumTreating patients who suffer from obsessive-compulsive spectrum disorders can cause mental health care professionals tremendous frustration or great satisfaction. Successful treatment of obsessive-compulsive disorders requires a complete understanding of the multiple etiologies involved, the psychotherapy required, and the sophisticated use of psychotropic medications. This session focuses on the clinically relevant evidenced-based treatment of obsessive-compulsive disorders and related spectrum disorders.Track: Anxiety Disordersspeaker: Stephen Sobel, MD

managing Chronic Pain in the elderlyThere are many specific challenges in treating chronic pain in the elderly that call for the skills and knowledge of mental health care professionals. Assessing pain in cognitively impaired patients requires careful observation of behaviors. Many mental disorders — includ-ing delirium, depression, and anxiety — can exacerbate pain and, in turn, the pain and pharmacologic treatments used can cause or worsen the mental disorders. This session discusses the assessment, pharmacologic and non-pharmacologic treatment, and management of pain and comorbid mental disorders in elderly patients.Tracks: Pain, Geriatric Psychiatryspeaker: Steven King, MD, MS

Treating the Whole Patient: schizophrenia — Cognition and metabolic functionThis session on schizophrenia will identify the neurobiological corre-lations inherent to schizophrenia and translate them to proper treat-ment selections while providing ongoing monitoring of the metabolic status, and advanced diagnostic strategies for negative and cognitive symptoms to achieve optimal patient adherence and outcomes.Tracks: Schizophrenia, Wellness speakers: Charles Raison, MD; Vladimir Maletic, MD, MS

12:00 p.m.–1:30 p.m.

Professional medical education PresentationTopic: depressive disordersLunch will be served.This presentation is provided by Forest Pharmacuetical, Inc.

12:00 p.m.–2:00 p.m.

bipolar 1 depression: an evidence-based approach to Clinical PracticeThe goal of this activity is to provide mental health professionals with an up-to-date clinical perspective of bipolar 1 depression, including an evidence-based dialogue on current and emerging therapies for consideration when individualizing management plans that best optimize outcomes.Track(s): TBAspeaker(s): TBAThis activity is supported by an educational grant from Sunovion Pharmaceuticals, Inc.

12:30 p.m.–2:00 p.m.

update on fibromyalgiaFibromyalgia is a chronic pain condition with a variety of psychi-atric comorbidities. The tremendous dysfunction that occurs in pa-tients with fibromyalgia can be improved through coordinated care often involving multiple subspecialties, especially mental health care professionals. This session describes the underlying patho-physiology of fibroymyalgia and comorbid psychiatric disorders, as well as the role of mental health care professionals in treating and managing patients with fibromyalgia.Track: Painspeaker: Bill McCarberg, MD

Can antipsychotics impact substance use or vocational Outcomes?Up to half of people with schizophrenia experience substance use disorders, and most are unemployed, but want to work. This session discusses the neurobiology of schizophrenia and addic-tion, the role antipsychotics in the treatment of schizophrenia and comorbid substance use disorders, and pharmacologic and non-pharmacologic strategies to treat and manage patients’ schizophrenia and comorbid substance use disorders to improve functional outcomes.Tracks: Schizophrenia, Substance Abuse, Addiction and Deterrence speaker: Douglas Noordsy, MD

dos and don’ts of depositionsAlmost all mental health care professionals are likely to have depositions taken over the courses of their careers. This session helps prepare mental health care professionals for their deposi-tions, including learning their rights, how to answer questions, and how to avoid common pitfalls.Track: Forensic Psychiatry speaker: Phillip Resnick, MD

unopposed exhibit Hall and education annex2:00 p.m.– 4:00 p.m

meeT THe eXPeRTs2:00 p.m–2:30 p.m, 2:45 p.m–3:15 p.m, and 3:30 p.m–4:00 p.m

TWP

16

®® sCienTifiC PROgRam saTuRdaY, nOvembeR 10, 2012


4:00 p.m.–5:30 p.m.

What the mental Health Care Professional should Know about Opioid PrescribingThe most widely prescribed drugs in United States are opioids; they are also widely abused. Psychiatrists frequently are asked to evaluate patients on opioid management. Primary care is the main prescriber of psychoactive drugs to pain patients and feel inad-equate to evaluate patient’s who demonstrate abberant behavior. Psychiatrists are uniquely positioned to help primary care deal with chronic pain patients with psychiatric issues. The goal of this ses-sion is to understand the issues related to opioid management for chronic pain and how psychiatry and interface with primary care.Track: Painspeaker: Bill McCarberg, MD

Physical exercise in the Treatment of Psychiatric disordersPsychiatric disorders are neurodegenerative and are associated with metabolic derangement. The research base demonstrat-ing the effects of physical exercise on neuronal function and psychiatric outcomes is rapidly expanding. This session reviews the evidence base addressing the effects of physical exercise on psychiatric disorders. Discussions include psychiatric disorders for which exercise can be effective, how to make treatment recommendations, and how to monitor outcomes.Tracks: Wellness, Mood Disordersspeaker: Douglas Noordsy, MD

The age equation: The impact of aging on mental illnessThe coming wave of 77 million baby boomers has the potential to transform both the expression and treatment of mental Illness in late life. This session examines current trends in the preva-lence of mental illness in late life and reviews ways in which the expression of various forms of mental illness, including depres-sion, anxiety, schizophrenia, personality disorders, and substance use disorders, change because of the aging process.Tracks: Geriatric Psychiatry, Mood Disordersspeaker: Marc Agronin, MD

Personalized medicine and Psychiatry: Why, What and How?Drugs are approved based on what they do in populations of patients whereas prescribers treat one individual at a time. A hallmark of good medication management is selecting the right medication and the right dose of that medication for each indi-vidual Personalized medicine is generally used to refer to how genetic differences amongst individuals affects their response to specific medications. That response may be increased or de-creased toxicity, tolerability and/or efficacy. This lecture reviews selected examples of genetic differences amongst patients and

how they affect response to commonly used medications.Tracks: Psychopharmacology, Neurology/Neuroscience speaker: Sheldon Preskorn, MD

Treating the Whole Patient expert Course: expert examination of Critical Risks versus benefits in the Treat-ment of schizophreniaThese engaging, small-group discussions aim to integrate scientific advances and theoretical knowledge into best clinical practice to achieve the optimal balance between treatment efficacy and potential risks, while promoting therapeutic collaboration, treatment adherence, and wellness practices. The intimate learning environment encourages engagement on possible diagnostic, treatment and management strategies using case examples. Enrollment is limited and pre-registration is required for all Expert Courses.Tracks: Schizophrenia, Wellness speaker: Vladimir Maletic, MD, MS; Charles Raison, MD

5:45 p.m.–7:15 p.m.

Hugs and drugs: Practical approaches to managing agitation in dementiaAgitation in elderly patients with dementia is problematic and common. This session’s systematic approach to problem behaviors in dementia includes principles of environmental assessment, and optimal medication strategies and non-pharmacologic manage-ment to empower caregivers, delay nursing home placement, and reduce the need for behavioral pharmacotherapy in some patients.Tracks: Dementia and Cognitive Disorders, Geriatric Psychiatry speaker: Kevin Gray, MD

Trends in mental Health malpracticeMalpractice suits against mental health care professionals have dou-bled in the last 25 years. Learn about the law of negligence, common causes of action against professionals, and how to reduce malpractice

TWP


®®sCienTifiC PROgRam sundaY, nOvembeR 11, 2012

risk by improving documentation and avoiding boundary violations.Track: Practice Managementspeaker: Phillip Resnick, MD

Why is it so difficult to develop effective Treatments for disturbed eating? new insights from neurobiologyWhy do people with anorexia nervosa restrict eating and become emaciated, or why do the obese become overweight? In recent years there is a new understanding of higher brain processes that modulate the rewarding aspect of food ingestion, or serve to in-hibit these processes. This session discusses how current treatments may affect, although with limited benefit, these top-down brain processes. Despite the frustration about limits of current therapy, a better understanding about the cause of dietary extremes is likely to result in more effective treatments in the future.Track: Eating Disordersspeaker: Walter Kaye, MD

sundaY, nOvembeR 11, 2012

8:30 a.m.–10:00 a.m.

Physical Comorbidities of depression: Case studies in alzheimer’s disease, Chronic Pain and diabetesThe goal of this series is to arm psychiatrists and other health care providers with the knowledge, confidence, and tools needed to recognize and provide treatment for physical comorbidities in patients with major depressive disorder to achieve optimal patient outcomes.Tracks: Mood Disorders, Dementia and Cognitive Disorders Painspeakers: Marc Agronin, MD; Clay Jackson, MD, DipTh; Rakesh Jain, MD, MPH; Bill McCarberg, MD, FAAFP, FABPMThis session is supported by an educational grant from Lilly USA, LLC

CME LLC is pleased to present the 4th Annual Treating the Whole Patient series at Psych Congress. Mental health care has

shifted from defining mental illness as emotional disorder to more broadly conceptualizing the mind-body connection. This cutting-edge approach aids understanding of the neurobiology of schizophrenia and depression and their effects on a patient; considers the role of medical comorbidities; addresses barriers to care; and promotes the affect of wellness on mental health.

TReaTing THe WHOle PaTienT eXPeRT COuRses

New for 2012 are the Expert Courses of Treating the Whole Patient: Integrating the Mind-Body Connection Into Mental Health Care. These engaging, small-group discussions aim to integrate scientific advances and theoretical knowledge into best clinical practice to achieve the optimal balance between treatment efficacy and potential risks, while promoting therapeutic collaboration, treatment adherence, and wellness practices.

The intimate learning environment encourages engagement on

possible diagnostic, treatment and management strategies using case examples. Enrollment is limited and pre-registration is required for all Expert Courses.

faculty: Jon W. Draud, MS, MD; Rakesh Jain, MD, MPH; Vladimir Maletic, MD, MS; Charles Raison, MD

ResTORing balanCe WORKsHOPsRejuvenate your mind and body by participating in meditation workshops. Unwind and relax after a long day of sessions and discover your inner self. Learn helpful techniques for your own wellbeing and that of your patients.

These workshops are not intended or eligible for Cme credit. Pre-registration is required for these sessions.

Pre-registration Sessions that require pre-registration will soon be available for selection. CME LLC will announce the opening of pre-registration for workshops and expert courses (limited-seating engagements) on www.psychcongress.com and via emails to all 2012 Psych Congress registered attendees. Pre-registration will be available on a first-come, first-served basis.

Integrating

into the

Mental Health Care

18

®® sCienTifiC PROgRam sundaY, nOvembeR 11, 2012


understanding the Placebo effect: Helping the mind to Heal itselfThere has been increasing talk in the popular press about how many of our common psychiatric treatments are no better than placebo. This session explores the complex neurobiological mechanisms of the placebo response, explains why it is a real and not imagined phenomenon, and suggests ways to enhance the placebo response to lead to better patient outcomes.Tracks: Neurology/Neuroscience, Psychotherapyspeaker: Andrew Penn, RN, MS, NP, CNS

sleep disorders: What’s new under the moon?More than half of all psychiatric patients complain of distur-bances of sleep and wakefulness. This session presents new developments in the understanding and management of a variety of sleep disorders, including insomnia, narcolepsy, sleep apnea syndrome, circadian rhythm disorders, and the parasom-nias. It also explores the psychiatric comorbidities associated with these conditions, and discusses how managing them may affect psychiatric complaints and conditions.Track: Sleep Disordersspeaker: Karl Doghramji, MD

Parkinson’s disease: Clinical update on Cognitive impairmentParkinson’s disease is the second most common neurodegen-erative disorder affecting older individuals. This session provides strategies to recognize and diagnose cognitive impairments in Parkinson’s disease, including Lewy body dementia. Discussions include effective therapies to manage associated cognitive and psychobehavioral problems.Tracks: Dementia and Cognitive Disorders, Neurology/Neurosciencespeaker: Kevin Gray, MD

10:15 a.m.–11:45 a.m.

addressing adherence and Treatment side effects in Patients with major depressive disorderThe goal of this activity is to provide psychiatrists and other mental health professionals with a better understanding of symptoms and treatment side effects associated with MDD as well as knowledge of new and emerging treatments with an emphasis on incorporat-ing measurement-based care into everyday practice to reduce side effects and improve treatment adherence.Track(s): TBAspeaker(s): TBAThis activity is supported by an educational grant from Forest Research Institute, Inc., a wholly-owned subsidiary of Forest Laboratories Inc.

understanding mental Health Through the law: a Review of landmark CasesMuch of the day-to-day practice of mental health care profession-als is founded on principles set forth by civil case law. This session reviews the history behind certain landmark cases that dictate current practice. Discussions include the history underlying psychi-atric principles such as duty to protect, involuntary hospitalization criteria, and capacity to consent to treatment.Tracks: Harm to Self and Others, Forensic Psychiatryspeaker: Almari Ginory, DO, MD

understanding and Reducing Risk for depressionDepression is the leading cause of disability in the world, and the effectiveness of antidepressant medication has not changed sig-nificantly over the past 40 years. This session presents an overview of important aspects of major depressive disorder in adults and children, such as cognitive and neural functioning, and reviews approaches for preventing the initial onset of this disorder.Tracks: Mood Disorders, Child and Adolescent Psychiatry

speaker: Ian Gotlib, PhDTreatment of bipolar depression: update 2012The depressive phase of bipolar disorder dominates the clini-cal course of this common illness, yet traditionally relatively few therapies have been studied or proven to be effective. Treatment utilization research suggests that there is a large gap between what is recommended in practice guidelines and what is often done in clinical practice. This session discusses the natural history of depres-sive episodes during the course of bipolar affective disorder, including both bipolar I and bipolar II disorders, as well as the evidence for and against the use of antidepressants, mood stabilizers, second-genera-tion antipsychotics, and depression-focused psychotherapies.Tracks: Mood Disorders, Psychopharmacologyspeaker: Michael Thase, MD

12:30 p.m.–2:00 p.m.

Harnessing the mind-body Connection for the Treatment of depression: behavioral and Pharmacologic interventions at the immune-stress system interfaceAlthough often effective, current treatment strategies for depression leave many patients with residual symptoms that predict both chronic disease and treatment resistance. This session discusses the limitations in our current therapeutic armamentarium; reviews relevant evolution-ary theory, suggesting that multiple brain-body signaling pathways may hold promise as interventions for the treatment of depression; examines evidence that targeting the peripheral immune system may offer promise as a therapeutic strategy for depressed patients with increased levels of inflammatory biomarkers; and explores the possibility that evolutionary processes might be harnessed to develop novel treatments based on the manipulation of body-based sensory pathways that signal the central nervous system in ways known to reduce depressive-like behavior in animal models and to improve depressive symptoms in humans.Tracks: Mood Disorders, Neurology/Neurosciencespeaker: Charles Raison, MD


®®sCienTifiC PROgRam sundaY, nOvembeR 11, 2012

baCK bY POPulaR demand

Restoring balance Workshops

After a full day of education, rejuvenate your body and spirit by participating in these exciting yoga and

meditation workshops.

THuRsdaY THROugH saTuRdaY7:30 p.m–8:30 p.m.

for the body: These yoga sessions will let your body recover and strengthen as you prepare for the next day’s

activities.

for the spirit: The meditation workshop will be led by Dr. Saundra Jain, who will help you unwind while providing insight

on how you can share these techniques with your patients.

These workshops are not intended or eligible for continuing medical education (CME) credit.

PRe-RegisTRaTiOn Will be ReQuiRed fOR THese sessiOns

fatigue among Health Care ProfessionalsFatigue is a common occurrence among health care profession-als, especially those in training. Although its impact has been well documented, health care professionals have only recently begun to address the difficulty. This session discusses the impact of fatigue on health care professionals, as well as methods to identify and alleviate fatigue in this population.Track: Wellnessspeaker: Karl Doghramji, MD

The mighty mini: unleashing the diagnostic Power of a simple Psychiatric assessment ToolQuick and accurate diagnostic needs exist in all practices, including psychiatry and primary care. The Mini International Neuropsychiatric Interview (MINI) is a 15-minute, highly validated, easy-to-use but underappreciated and underused instrument that leads to accurate DSM-IV diagnoses. This session introduces participants to the MINI and teaches them how to use it in everyday clinical practice.Track: Assessment and Adherencespeaker: Saundra Jain, MA, PsyD, LPC

advances in the Treatment of anorexia nervosa and bulimia nervosa — What is new and Where are We going?Anorexia nervosa (AN) and bulimia nervosa (BN) most commonly occur in young women who develop extremes in eating behaviors, weight, and body image distortions. These disorders tend to have limited responses to treatments; however, new treatment approaches are leading to improved patient outcomes. This session discusses psychological and pharmacologic treatment approaches for patients with AN and BN.Track: Eating Disordersspeaker: Walter Kaye, MD

2:15 p.m.–3:45 p.m.

it’s Only a dog: The assessment and Treatment of animal abuseAnimal abuse is a common maladaptive behavior that is increasingly being recognized in various clinical settings. This session provides an introduction to the relationship between animal abuse and domestic violence, and information about how to assess and treat both juve-niles and adults who abuse animals.Tracks: Abuse/Trauma, Psychotherapyspeakers: Lorin Lindner, PhD; Kenneth J. Shapiro, PhD

improving suicide Risk assessment using Travel-Related studiesAccurate suicide assessment is crucial for the safety of our patients. This session will review critical risk factors and suggest methods to integrate clinical information to help determine when hospitalization and other protective measures are indicated. Critical factors will be highlighted in studies of the modulation in suicide risk when people travel outside their county of residence to improve the accuracy of suicide assessment.Track: Harm to Self and Othersspeaker: Paul Zarkowski, MD

Treatment of the early stages of schizophrenia — Practical approachesResearch data has reported on the impact of reducing the duration of untreated psychosis, yet the field has not been as explicit in the specific treatment paradigms for these patients. The goal of this session is to advance the participant’s knowledge from simply identifying the early stages of schizophrenia to the taking the appropriate interventions for the prodrome and first episode schizophrenia. An important issue is the dosing and side-effect monitoring of pharmacologic treatment. Further, specific psychoeducational interventions will be discussed.Track: Schizophrenia speaker: S. Charles Schulz II, MD

PRe-ORdeR YOuR 2012COmPReHensive sessiOn sYllabus

CHOICE OF PRINTED OR ELECTRONIC FORMAT (PDF)

add to your cart when registering to guarantee

that your syllabus will be waiting for you at check-in

®®

20

®® eduCaTiOn anneX


EDUCATION ANNEX leaRning and neTWORKing OPPORTuniTies!

Get the most value out of Psych Congress. Extend your educational opportunities throughout all aspects of the conference and exhibit hall. At the educational annex, you’ll find the poster pavilion, product theaters, meet the experts sessions, and networking lounges — all to provide you with a high-value educational experience that helps you enhance your practice and improve patient care.

Poster PavilionTake in the latest clinically relevant information about cutting-edge research, innovative projects and programs and provide an opportunity for peer-to-peer education. Different presentations are featured throughout the two exhibit hall days, so visit each day for insightful discourse with the presenters. Poster presentations are not intended or eligible for CME credit. Poster abstracts are now being accepted. for more information, visit http://psychcongress.com/poster-sessions.

Professional medical education Presentations (non-Cme)Uncover the latest information, data, and research findings with disease-state or product-specific presentations. Ask questions of key experts and industry representatives, and assess the value to your patient care. Seating is limited and available on a first-come, first-served basis. Professional Medical Education presentations are not intended or eligible for CME credit.

meet the expertsEngage with the 2012 Psych Congress Advisory Board in small-group question-and-answer sessions on topics that are most important to you, your patients and your practice. These intimate discussions will take place in the CME LLC booth in the exhibit hall. These sessions are not intended or eligible for CME credit. Schedule TBA.

Passport to Prizes Submit your passport to prizes entry form at the CME LLC booth during exhibit hall hours each day to be entered to win exciting prizes. The grand prize winner will receive a 2013 Psych Con-gress registration, including a hotel stay — a $3,000 value!


®®eXHibiT Hall

view exhibitor profiles and contact information at psychcongress.com/current-exhibitors.

ACIGI Relaxation / Dr. Fuji Alkermes, Inc. Allina Health Alpha Health Systems American Physician InstituteAmerican Professional Agency, Inc. American Psychiatric Association American Psychiatric Publishing, Inc. AssureRx Health Austen Riggs Center Avanir Pharmaceuticals BioBehavioral Diagnostic (BioBDx)Civilian Medical CorpsCME LLC CTP — Dragon Medical Practice EditionCurrent Psychiatry Department of Veterans Affairs (HRRO)Diamond HealthcareForest Pharmaceutical, Inc. Genentech, A Member of the Roche GroupGenomindThe Gideons InternationalGlobal Medical Staffing Infinite Therapeutics International Bipolar Foundation Jackson & Coker Jazz PharmaceuticalsKaiser PermanenteLogistics HealthLocumTenens.comLundbeck MAPS — Multidisciplinary Association for Psychedelic StudiesMedical Doctor Associates

Menninger Clinic MyCardio/SleepImageMylan Inc. Nature Bright CompanyNetsmart Technologies Neuronetics, Inc.NextWave PharmaceuticalsNorthern Light TechnologiesNovartis Pharmaceutical CorporationOtsuka America Pharmaceuticals, Inc.Pamlab, LLC, CerefolinNAC and DelpinPhysician Engineered ProductsPractical Recovery Professional Risk Management Services Psychiatric Times Psychiatrists OnlyQTC Medical ServicesRADMAX, LTDRegistry of Physician SpecialistsRidge DiagnosticsShire USSouthcentral FoundationSouthwest Behavioral Health Services Southwest Network Spartanburg Regional Healthcare System Sunovion Pharmaceuticals, Inc. The TOVA CompanyUnion of Psychiatric Nurses Valant Medical Solutions Validus Pharmaceuticals LLC Verilux, Inc. VISTA Staffing Solutions

Note: as of August 22For exhibiting information, contact Jennifer Griffith at 949-302-0734 or visit www.psychcongress.com

EXHIBIT HALL inTeRaCT WiTH mORe THan 85 eXHibiTORs!

The 2012 Psych Congress will feature the most dynamic exhibit hall, showcasing more than 85 prestigious companies. Gain direct access to company representatives who will provide information on how their products and services can benefit your practice and patients. On the exhibit floor you will find the latest offerings from academic book publishers, meet with pharmaceuticals companies, speak with employment recruiters, and receive valuable giveaways.

22

®® SCIENTIFIC PROGRAM

RegisteR eaRly and saveRegisteR today: www.psychcongRess.com22

®® HOTel and TRavel infORmaTiOn


san diego Convention Center111 W. Harbor DriveSan Diego, CA 92101www.visitsandiego.com

2012 Psych Congress will be held at the San Diego Conven-tion Center in San Diego, CA, adjacent to the beautiful Marina Park on the San Diego Bay. The conference and hotel are less than 4 miles from San Diego International Airport (SAN).

Headquarter Hotel/ReservationsSan Diego Marriott Marquis & Marina333 West Harbor DriveSan Diego, CA 92101800-228-9290 www.marriott.com

Reservations are now being accepted. A limited block of rooms is being held at the Marriott Marquis for conference attendees and exhibitors at a discounted rate of $259 USD per night for single or double occupancy. To receive the special reduced rate, you must reserve before Thursday, October 4, 2012, and reference the group code psypsyi. The room rates will be available 3 days pre- and post-conference, based on availability. We encourage you to book rooms early, as these hotels sell out quickly.

Please note that, upon booking your reservation, your credit card will be charge a deposit equal to one night’s room and tax. This deposit is nonrefundable.

Check-in/Check-out Check-in time is 4:00 p.m. Check-out time is 12:00 noon. Express checkout is available.

Changes/CancellationsPlease refer to your hotel confirmation for instructions.

aCCOmmOdaTiOns fOR PeRsOns WiTH sPeCial needs Cme llC complies with the legal requirements of the americans with disabilities act and the rules and regula-tions thereof. if you require accommodations due to a special need, please call 609-371-1137 before you arrive at the 2012 Psych Congress, and Cme llC will do its best to accommodate you.

airline and Transportation informationAirfare discounts for attendees are available through various airlines. Flight-booking information:

American Airlineswww.AA.com (800) 433-1790 Discount code: 34N2BE

Continental/United Airlineswww.continental.com (800) 468-7022 Discount code: ZM9G181044

Delta Airlineswww.delta.com (800) 328-1111 Discount code: NM8ZA

Car rental discounts for attendees are available through the following companies:

Avis www.avis.com (800) 331-1600Discount code: D008399

Hertz www.hertz.com (800) 654-2240Discount code: CV# 022L3379

SAN DIEGO find OuT WHY iT’s Called “ameRiCa’s finesT CiTY’

The San Diego Marriott Marquis & Marina is just steps from downtown San Diego, best known as the Gas Lamp Quarter. Close attractions for everyone include championship golf and family friendly attractions such as the San Diego Zoo, Sea World San Diego and Legoland California. Highlights of local attractions include the Midway Aircraft Carrier Museum, harbor excursions, Old Town Trolley Tours, excellent dining and great nightlife. For more, go to www.visitsandiego.com.

Register online www.psychcongress.com, by fax 610-560-0502 or by mail. FoR inFoRmation call 800-237-7285, ext. 233 2323

COnfeRenCe RegisTRaTiOn

aTTendee infORmaTiOn (Please print)r Mr. r Mrs. r Ms. r Male r Female__________________________________________________________________________First name MI Last name__________________________________________________________________________Suffix/credentials (Jr., III, RN, MD, DPM, etc) __________________________________________________________________________Name as it will appear on your badge including credentials (max 30 characters)Please note that commas and spaces are considered characters.

__________________________________________________________________________Title__________________________________________________________________________Department Company/organization name__________________________________________________________________________Address 1__________________________________________________________________________Address 2__________________________________________________________________________City State Zip Country__________________________________________________________________________Telephone Fax__________________________________________________________________________Email address (confirmations will be sent via e-mail)

PROfessiOnal infORmaTiOn Graduation Year_________ Position____________________ Profession: r Physician r Nurse r Nurse practitioner r Physician assistant r Psychologist r Counselor r Pharmacist r Social worker r Other

Practice setting 1: r Academic r Group practice (2–5) clinicians r Group practice (6–9 clinicians)r Group practice (10+ clinicians) r Private practice r HMO r Community hospital/facility r Private hospital/facility r VA/federal hospital/facility r State hospital/facility r Other

Practice setting 2: r Academic r Group practice (2–5) clinicians r Group practice (6–9 clinicians)r Group practice (10+ clinicians) r Private practice r HMO r Community hospital/facility r Private hospital/facility r VA/federal hospital/facility r State hospital/facility r Other

sYllabus PuRCHaser 2012 Psych Congress printed syllabus ($75 before november 2; $100 on-site) You get two bound volumes of printed comprehensive session handouts — ideal for note-taking dur-ing the sessions and a handy reference tool after Psych Congress concludes — at badge pickup. r 2012 Psych Congress flash drive syllabus ($50 before november 2; $75 on-site) You get a credit card-sized USB drive containing all session handouts. You can access them anywhere, anytime — view on screen, or print for note-taking. Retrievable at badge pickup.

CanCellaTiOn POliCYIf you cannot attend, notify us in writing by email, fax or post. Cancellations will be honored as follows: • Received by Friday, Oct. 4, 2012: full refund, minus $50 processing fee• Received Oct. 5 through Nov. 2, 2012: 50% refund, minus $50 processing fee • Received from Nov. 3, 2012: No refund. If you do not cancel or do not attend, you are still

responsible for full payment. There are no exceptions to these policies. Payments made may not be applied to tuition for future Psych Congress events, nor other meetings or products offered by CME LLC. For full details, visit www.psychcongress.com.

meTHOd Of PaYmenT Choose from the following options:r Check payable to HMP Communications. All checks must be drawn on a U.S. bank in U.S. funds. Mail to 83 General Warren Blvd., Suite 100; Malvern, PA 19355.

Credit Card (check one)r MasterCard r Visa r American Express

Name on card ______________________________________Billing post code _____________

Credit card No. _______________________________________________________________

Expiration date _________________________________ Security code ___________________

__________________________________________________________________________Signature of cardholder (required)

Registration for the 25th annual U.s. Psychiatric and Mental health congress nov. 8-11, 2012 at The san diego Convention Center. includes access to all conference sessions and exhibit hall activities. industry-supported symposia and professional medical education sessions require pre-registration.

2012 aTTendee RaTes• August 4–October 5 $699• October 6–November 2 $799• On-site $1,099

83 G

ener

al W

arre

n B

lvd.

Sui

te 1

00M

alve

rn, P

A 1

9355

ww

w.h

mpc

omm

unic

atio

ns.c

om

THRe

e ea

sY W

aYs

TO R

egis

TeR:

1 Co

mpl

ete

regi

stra

tion

at

ww

w.p

sych

cong

ress

.com

.

2 Ca

ll (8

00) 2

37-7

285,

ext

. 233

, an

d ha

ve y

our c

redi

t car

d

info

rmat

ion

hand

y.

3 Fi

ll ou

t and

fax

the

enclo

sed

re

gist

ratio

n fo

rm to

610

-560

-050

2.

Reg

isTe

R bY

OCT

Obe

R 5

WiT

H Y

Ou

R PR

Ofe

ssiO

na

l d

isCO

un

T fO

R

On

lY $

699.

LLC

, ™ ®

®®

no

ve

mb

er

8-1

1, 2

012

Sa

n d

ieg

o C

on

ve

nt

ion

Ce

nt

er

Sa

n d

ieg

o, C

a

®®CO

MPL

ETE

SCHE

DULE

&

PROG

RAM

SC

IEN

TIF

IC P

ro

gr

am

Ch

oo

SE

Fr

om

mo

rE

Th

aN

80

Ex

CIT

INg

SE

SS

IoN

S •

Int

er

ac

t w

Ith

ov

er

85

ex

hIb

Ito

rs

no

ve

mb

er

8-1

1, 2

012

• S

an

die

go

Co

nv

en

tio

n C

en

te

rr

eg

Ist

er

be

fo

re

oc

to

be

r 5

th

fo

r o

nly

$69

9!

ca

ll

: 800

-237

-728

5 ex

t. 2

33 o

r v

IsIt

ps

yc

hc

on

gr

es

s.c

om

Documents

25th Annual U.S. Psychiatric and Mental Health Congress